RBC Capital raised the firm’s price target on Bausch + Lomb (BLCO) to $21 from $19 and keeps an Outperform rating on the shares ahead of its Q4 results. The firm is positive on FX tailwinds and also expects 2026 guidance and Rx DED – dry-eye disease – portfolio to be key areas of focus, the analyst tells investors in a research note.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BLCO:
- Bausch + Lomb Sets February Date to Report 2025 Results
- Bausch + Lomb price target raised to $19 from $17 at Goldman Sachs
- Evercore ISI upgrades four, downgrades six in MedTech and Tools
- Bausch + Lomb downgraded to In Line from Outperform at Evercore ISI
- Bausch + Lomb refinances term loans, extends maturities